Impact of the use of rivaroxaban in the length of stay of patients treated for acute venous thromboembolism in a developing country
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:204 |
|---|---|
| Enthalten in: |
Thrombosis research - 204(2021) vom: 15. Aug., Seite 143-145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boietti, B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9NDF7JZ4M3 |
|---|
| Anmerkungen: |
Date Completed 02.08.2021 Date Revised 02.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.thromres.2021.01.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321526074 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321526074 | ||
| 003 | DE-627 | ||
| 005 | 20231225180007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.thromres.2021.01.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321526074 | ||
| 035 | |a (NLM)33593595 | ||
| 035 | |a (PII)S0049-3848(21)00030-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boietti, B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of the use of rivaroxaban in the length of stay of patients treated for acute venous thromboembolism in a developing country |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2021 | ||
| 500 | |a Date Revised 02.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Deep vein thrombosis | |
| 650 | 4 | |a Length of stay | |
| 650 | 4 | |a Pulmonary embolism | |
| 650 | 4 | |a Rivaroxaban | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 700 | 1 | |a Fili, S |e verfasserin |4 aut | |
| 700 | 1 | |a Peuchot, V |e verfasserin |4 aut | |
| 700 | 1 | |a Tabares, A |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez, F |e verfasserin |4 aut | |
| 700 | 1 | |a Gándara, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis research |d 1974 |g 204(2021) vom: 15. Aug., Seite 143-145 |w (DE-627)NLM000010839 |x 1879-2472 |7 nnns |
| 773 | 1 | 8 | |g volume:204 |g year:2021 |g day:15 |g month:08 |g pages:143-145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.thromres.2021.01.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 204 |j 2021 |b 15 |c 08 |h 143-145 | ||